• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嗜铬细胞瘤和副神经节瘤的发病机制:从遗传异质性中学习。

Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

机构信息

Department of Medicine/Division of Hematology and Medical Oncology, Cancer Therapy and Research Center, Greehey Children Cancer Research Institute, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Lab 5053-R3, MC 7880, San Antonio-TX 78229-3900, USA.

出版信息

Nat Rev Cancer. 2014 Feb;14(2):108-19. doi: 10.1038/nrc3648. Epub 2014 Jan 20.

DOI:10.1038/nrc3648
PMID:24442145
Abstract

The neuroendocrine tumours pheochromocytomas and paragangliomas carry the highest degree of heritability in human neoplasms, enabling genetic alterations to be traced to clinical phenotypes through their transmission in families. Mutations in more than a dozen distinct susceptibility genes have implicated multiple pathways in these tumours, offering insights into kinase downstream signalling interactions and hypoxia regulation, and uncovering links between metabolism, epigenetic remodelling and cell growth. These advances extend to co-occurring tumours, including renal, thyroid and gastrointestinal malignancies. Hereditary pheochromocytomas and paragangliomas are powerful models for recognizing cancer driver events, which can be harnessed for diagnostic purposes and for guiding the future development of targeted therapies.

摘要

神经内分泌肿瘤嗜铬细胞瘤和副神经节瘤在人类肿瘤中具有最高的遗传性,使得通过家族遗传可以追踪到基因改变与临床表型的关系。十多个不同的易感基因的突变使这些肿瘤中的多个途径受到牵连,为激酶下游信号转导相互作用和低氧调节提供了深入了解,并揭示了代谢、表观遗传重塑和细胞生长之间的联系。这些进展还扩展到了伴发肿瘤,包括肾、甲状腺和胃肠道恶性肿瘤。遗传性嗜铬细胞瘤和副神经节瘤是识别癌症驱动事件的有力模型,可用于诊断目的,并为未来靶向治疗的发展提供指导。

相似文献

1
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.嗜铬细胞瘤和副神经节瘤的发病机制:从遗传异质性中学习。
Nat Rev Cancer. 2014 Feb;14(2):108-19. doi: 10.1038/nrc3648. Epub 2014 Jan 20.
2
Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.嗜铬细胞瘤和副神经节瘤:近期分子遗传学进展及恶性肿瘤标准更新。
Adv Anat Pathol. 2015 Sep;22(5):283-93. doi: 10.1097/PAP.0000000000000086.
3
Familial pheochromocytomas and paragangliomas.家族性嗜铬细胞瘤和副神经节瘤。
Mol Cell Endocrinol. 2014 Apr 5;386(1-2):92-100. doi: 10.1016/j.mce.2013.07.032. Epub 2013 Aug 7.
4
[Diagnostic approach of pheochromocytomas and paragangliomas].[嗜铬细胞瘤和副神经节瘤的诊断方法]
Hipertens Riesgo Vasc. 2019 Jan-Mar;36(1):34-43. doi: 10.1016/j.hipert.2018.06.003. Epub 2018 Aug 2.
5
Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.嗜铬细胞瘤和副神经节瘤中的缺氧通路突变
Cytogenet Genome Res. 2016;150(3-4):227-241. doi: 10.1159/000457479. Epub 2017 Feb 24.
6
Genomic Landscape of Pheochromocytoma and Paraganglioma.嗜铬细胞瘤和副神经节瘤的基因组图谱
Trends Cancer. 2018 Jan;4(1):6-9. doi: 10.1016/j.trecan.2017.11.001. Epub 2017 Nov 26.
7
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.在嗜铬细胞瘤和副神经节瘤中 HIF2A 突变的体内和体外致癌作用。
Endocr Relat Cancer. 2013 May 21;20(3):349-59. doi: 10.1530/ERC-13-0101. Print 2013 Jun.
8
An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.20 年来嗜铬细胞瘤和副神经节瘤遗传研究概述。
Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101416. doi: 10.1016/j.beem.2020.101416. Epub 2020 Mar 10.
9
Familial pheochromocytoma.家族性嗜铬细胞瘤
Hormones (Athens). 2009 Jan-Mar;8(1):29-38. doi: 10.14310/horm.2002.1219.
10
Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.嗜铬细胞瘤和副神经节瘤分子发病机制的最新见解
Endocr Pathol. 2006 Summer;17(2):97-106. doi: 10.1385/ep:17:2:97.

引用本文的文献

1
FDA fast-track approval of belzutifan is a milestone in rare cancer therapy.美国食品药品监督管理局(FDA)对贝佐替凡的快速批准是罕见癌症治疗领域的一个里程碑。
Nat Rev Endocrinol. 2025 Sep 11. doi: 10.1038/s41574-025-01183-z.
2
Paediatric Paraganglioma with Variant of Unknown Significance on Genetic Testing.基因检测显示具有意义未明变异的小儿副神经节瘤
Case Rep Oncol. 2025 Jan 22;18(1):255-261. doi: 10.1159/000543615. eCollection 2025 Jan-Dec.
3
Distinct proteomic and acylproteomic adaptations to succinate dehydrogenase loss in two cell contexts.

本文引用的文献

1
The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function.肿瘤易感基因TMEM127在肾细胞癌中发生突变并调节内溶酶体功能。
Hum Mol Genet. 2014 May 1;23(9):2428-39. doi: 10.1093/hmg/ddt638. Epub 2013 Dec 13.
2
Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.HIF2A相关的红细胞增多症-副神经节瘤综合征中的镶嵌现象。
J Clin Endocrinol Metab. 2014 Feb;99(2):E369-73. doi: 10.1210/jc.2013-2600. Epub 2013 Nov 25.
3
Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.
在两种细胞环境中对琥珀酸脱氢酶缺失的不同蛋白质组学和酰基蛋白质组学适应性变化
bioRxiv. 2025 Aug 2:2025.08.01.668168. doi: 10.1101/2025.08.01.668168.
4
The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management.嗜铬细胞瘤治疗的围手术期生化及临床考量
Int J Mol Sci. 2025 Jun 25;26(13):6080. doi: 10.3390/ijms26136080.
5
Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors.缺氧诱导因子-2α(HIF-2α)通路抑制剂。
J Kidney Cancer VHL. 2025 Jul 2;12(3):1-15. doi: 10.15586/jkc.v12i3.413. eCollection 2025.
6
Editorial: Recent advances in pheochromocytoma and paraganglioma: molecular pathogenesis, clinical impacts, and therapeutic perspective, volume II.社论:嗜铬细胞瘤和副神经节瘤的最新进展:分子发病机制、临床影响及治疗前景,第二卷
Front Endocrinol (Lausanne). 2025 May 2;16:1605189. doi: 10.3389/fendo.2025.1605189. eCollection 2025.
7
Predictors of postoperative recurrence of pheochromocytoma: a monocentric study.嗜铬细胞瘤术后复发的预测因素:一项单中心研究。
BMC Surg. 2025 Apr 25;25(1):179. doi: 10.1186/s12893-025-02824-w.
8
[A case report of malignant paraganglioma with lymph node and liver metastasis in the jugular foramen area].[一例颈静脉孔区恶性副神经节瘤伴淋巴结及肝转移的病例报告]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025 May;39(5):486-487;490. doi: 10.13201/j.issn.2096-7993.2025.05.017.
9
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.在全身缺氧条件下发生的人类肿瘤以及生活在高海拔地区人群中的趋同遗传适应。
Cancer Discov. 2025 May 2;15(5):1037-1062. doi: 10.1158/2159-8290.CD-24-0943.
10
Pheochromocytomatosis Treated By Radio-Guided Surgery.放射性引导手术治疗嗜铬细胞瘤病
AACE Clin Case Rep. 2020 Dec 28;3(2):e170-e175. doi: 10.4158/EP151053.CR. eCollection 2017.
琥珀酸脱氢酶相关副神经节瘤/嗜铬细胞瘤综合征患者中的非嗜铬细胞瘤(PCC)/副神经节瘤(PGL)肿瘤:临床病理和分子分析。
Eur J Endocrinol. 2013 Nov 22;170(1):1-12. doi: 10.1530/EJE-13-0623. Print 2014 Jan.
4
The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.嗜铬细胞瘤的特征及其对 2 型多发性内分泌肿瘤患者总生存的影响。
J Clin Endocrinol Metab. 2013 Nov;98(11):E1813-9. doi: 10.1210/jc.2013-1653. Epub 2013 Sep 12.
5
A Central role for mTOR in lipid homeostasis.mTOR 在脂质动态平衡中的核心作用。
Cell Metab. 2013 Oct 1;18(4):465-9. doi: 10.1016/j.cmet.2013.08.002. Epub 2013 Aug 22.
6
Signatures of mutational processes in human cancer.人类癌症中的突变过程特征。
Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14.
7
Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells.还原性谷氨酰胺代谢是细胞中α-酮戊二酸与柠檬酸比值的功能。
Nat Commun. 2013;4:2236. doi: 10.1038/ncomms3236.
8
One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.未经治疗的恶性嗜铬细胞瘤和副神经节瘤患者的一年无进展生存。
J Clin Endocrinol Metab. 2013 Oct;98(10):4006-12. doi: 10.1210/jc.2013-1907. Epub 2013 Jul 24.
9
The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage.嗜铬细胞瘤和副神经节瘤的遗传图谱:体细胞突变占据核心地位。
J Clin Endocrinol Metab. 2013 Jul;98(7):2679-81. doi: 10.1210/jc.2013-2191.
10
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.Myc 和 mTOR 在蛋白质合成控制的共同节点上汇聚,赋予 Myc 驱动型癌症的合成致死性。
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11988-93. doi: 10.1073/pnas.1310230110. Epub 2013 Jun 26.